Creative Biolabs expands circRNA research services with analysis and delivery tools

Creative Biolabs said it is broadening support for circular RNA research with services that span circRNA analysis, custom lipid nanoparticle formulation and reporter circRNA products. The integrated workflow is aimed at helping researchers verify circularization, test function and improve delivery as circRNA moves toward therapeutic and experimental use.

Why it matters: - circRNA is drawing interest in RNA biology and therapeutic research because its covalently closed structure can resist exonucleases and support longer intracellular persistence. - Engineered coding circRNAs may also enable sustained expression, but researchers still need to prove circularization, measure function and solve delivery problems before results are reliable. - A workflow that connects analysis, validation and delivery can reduce trial-and-error in circRNA development.

What happened: - Creative Biolabs introduced an integrated set of circRNA research solutions covering analytical characterization, functional evaluation, custom lipid nanoparticle, or LNP, formulation and reporter circRNA products. - The company says the portfolio is designed to support research from early investigation through delivery studies. - Creative Biolabs included a link to its gene therapy and circRNA research offerings: Explore Creative Biolabs' gene therapy and circRNA research solutions.

The details: - The circRNA analysis services can include circRNA identification and back-splice junction analysis. - The services can also cover expression profiling and quantitative evaluation. - Bioinformatics analysis of circRNA candidates is part of the offering. - Cellular and tissue localization work is available. - Functional validation in relevant experimental models is also included. - Combining multiple analytical approaches can help distinguish circRNA signals from linear transcripts and assay artifacts. - Creative Biolabs said custom LNP formulation services can be tailored to individual circRNA research requirements. - Formulation development can include optimization and physicochemical characterization. - The characterization can assess particle size, polydispersity, zeta potential and encapsulation efficiency. - Researchers can add in vitro and in vivo studies to examine cellular uptake, expression, biodistribution and other project-specific endpoints. - Creative Biolabs also offers reporter circRNA products for transfection, expression and delivery performance studies. - The reporter products can be used in early-stage optimization before researchers move to more complex constructs.

Between the lines: - The company is positioning circRNA research as a connected pipeline rather than a set of separate services. - That approach reflects a broader challenge in the field: a promising RNA construct can still fail if circularization, expression or delivery is not validated step by step. - The emphasis on characterization plus LNP delivery suggests Creative Biolabs is targeting both discovery work and translational research needs.

What's next: - Creative Biolabs says researchers can use the combined workflow to identify bottlenecks earlier and make better decisions for follow-on studies. - The company is steering scientists toward its broader gene therapy and circRNA research platform for future RNA projects. - Creative Biolabs describes its global biotechnology services as covering gene therapy, circRNA research, nucleic acid development, delivery systems, analytical characterization and preclinical evaluation.

The bottom line: - Creative Biolabs is betting that circRNA research will move faster when analysis, validation and delivery are developed together, not in isolation.